CASE REPORT

Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report

Alvise Tosoni 1*, Mario Cutrone 2, Maurizio Dalle Carbonare 3, Andrea Pettenazzo 1, Giorgio Perilongo 4 and Stefano Sartori 4

Abstract

Background: Propranolol has become the first-line treatment for complicated Infantile Hemangioma (IH), showing so far a good risk-benefit profile.

Case presentation: We report the case of a toddler, on propranolol, who suffered cardiac arrest during an acute viral infection. She had a neurally-mediated syncope that progressed to asystole, probably because of concurrent factors as dehydration, beta-blocking and probably individual susceptibility to vaso-vagal phenomena. In fact a significant history of breath-holding spells was consistent with vagal hyperactivity.

Conclusions: The number of patients treated with propranolol for IHs will increase and sharing experience will help to better define the safety profile of this drug.

Keywords: Adrenergic beta-blockers, Asystole, Child

Background

Infantile hemangiomas (IH) are the most common vascular tumors of childhood affecting about 5% of infants. They are benign tumors that usually appear in the first few weeks of life and they go through a rapid proliferative phase that lasts several months before a slower involution phase begins. Many of these lesions resolve spontaneously with few residuals. Nevertheless some IHs can be functionally significant for size and/or location and therefore deserve medical treatment. Since propranolol has been discovered to clearly reduce hemangiomas it has gained a primary role in the treatment of high-risk IHs and so far it has shown a favorable risk-benefit profile [1].

A pediatric propranolol formulation (Hemangeol/Hemangiol) has been approved by FDA (Food and Drug Administration) and EMA (European Medicine Agency) in 2014 specifically for the treatment of IH.

We report the case of a toddler who suffered a cardiac arrest while on treatment with propranolol for IH.

Case description

A 14-month-old white female toddler was referred to a service of pediatric dermatology for a wide IH on the interscapular back area. The lesion appeared after birth and grew rapidly in the first few months. She was first followed in another center where laser therapy was attempted unsuccessfully. On examination the hemangioma was described as remarkable in size, tense and not showing clear signs of involution yet. For its position the lesion was uncomfortable and exposed to possible trauma as well as pressure and rubbing when the child was laying on the back (Fig. 1a). Even if she was not an infant anymore, she was deemed to meet the criteria for medical treatment in order to avoid possible complications and a spontaneous involution with potentially aesthetical damages. A decision was taken to try oral beta-blocker.

History and physical examination were unremarkable for cardiac problems; anyway she underwent an ECG and an echocardiogram, which were normal. Treatment was initiated at a dose of 0.5 mg/kg/die (in 2 daily doses) and increased to a target dose of 2 mg/kg/die during a two-day hospital admission in order to monitor for possible side effects (in particular bradychardia, hypotension) as

* Correspondence: Alvise.Tosoni@aopd.veneto.it
1Department of Women’s and Children’s Health, Pediatric Intensive Care Unit, University Hospital of Padua, via Giustiniani 3, 35128 Padova (PD), Italy
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
recommended by a group of experts [2]. The drug was well tolerated, so she was discharged home. Propranolol was prepared as a solution (1 mg/ml) by a pharmacist according to medical prescription. Parents were informed to hold therapy in case of gastrointestinal infections or any other case of reduced oral intake to avoid the risk of hypoglycemia. The response to treatment was significant as documented at two follow-up visits at 8 and 37 days from initiation (Fig. 1b-c).

Forty days into the treatment the child developed an upper respiratory tract infection. After a couple of days she was reported to have some fatigability, lack of appetite and decreased oral fluid intake. The parents were planning to withhold the evening dose of propranolol, but 8 h after the morning dose, the child fainted without regaining consciousness, during an effort to pass stool. EMS (Emergency Medical Services) was called and chest compressions were started in few minutes by a trained neighbor. On arrival EMS found her asystolic and carried on cardiopulmonary resuscitation for 20 min before return of spontaneous circulation. She arrived to pediatric ICU hemodynamically stable without requirement of inotropic support. Blood work showed hypernatremia (Na 156 mmol/L), other electrolytes and glycaemia were in normal ranges. Hemoglobin was normal (121 g/L, MCV 78.4 fL). White blood cell count was unremarkable (7700/uL) and CRP only mildly elevated (16 mg/L). Adenovirus and Rhinovirus were isolated from nasal swab. Parents provided us with the bottle of propranolol solution whose concentration was tested and confirmed to be correct. Twelve hours after admission she developed status epilepticus despite all neuroprotective strategies were taken. A brain MRI revealed severe diffuse hypoxic-ischemic injuries. ECGs, ECG-Holter, echocardiogram were confirmed to be normal. She tested negative for known mutations in a panel of 86 genes causing cardiomyopathies and channelopathies implicated in arrhythmias (Table 1). She also was tested for genetic polymorphisms possibly responsible for a slower propranolol metabolism (Table 2). She was found to carry four single nucleotide polymorphisms (SNP) in genes encoding for enzymes involved in phase I (CYP2D6, CYP2C19) and II (UGT1A7, UGT2B7) metabolism, and one SNP in a gene (ORM1) encoding for a plasma protein (alpha-1-lacid glycoprotein 1) involved in the binding and transport of many drugs.

Notably, a history of frequent pale and cyanotic breath-holding spells (BHS) emerged.

The patient was transferred out of the ICU on day 15 after admission. She was finally discharged from the hospital 55 days after the event with poor neurologic outcomes as spastic tetraparesis, epilepsy and severe cognitive impairment.

**Discussion**

We report the case of a 14-month old toddler on treatment with oral propranolol for IH who, during a viral illness, suffered a cardiac arrest, which resulted in a severe neurologic outcome. To our knowledge there is only another report of a case of cardiac arrest in a child with bronchiolitis while on propranolol for IH [3].

A recently published RCT [4] has confirmed that oral propranolol at a dose of 3 mg/kg/day for 6 months is effective. In this study only one patient on propranolol (1/401) was described to suffer a serious adverse event like bradycardia in the context of enterocolitis. To follow, the American Academy of Pediatrics published a comprehensive guidance for the diagnosis and management of IHs [5]. The authors report how propranolol has become the first-line drug for complicated IHs. A complete history and physical examination, focusing especially on cardiac and respiratory problems, is necessary to investigate the child’s suitability for treatment. Even though many clinicians prefer to have an ECG or even a cardiology consultation, a cardiac screening would appear of limited value in face of unremarkable cardiac history and examination. Reported contraindications are sinus bradycardia, hypotension, heart-block, heart failure, cardiogenic shock, reactive airways, hypoglycemia, hypersensitivity to the drug. Most commonly reported side effects are diarrhea, sleep disorders, cool extremities, reactive airways, hypoglycemia.
Predictable important risks as bronchospasm, bradycardia, hypotension and hypoglycemia are infrequent and rarely lead to treatment discontinuation. It is important to note that, as at now, there are not precise guidelines on how to initiate the treatment and how to monitor for side effects. Yet, in recent publications, authors have suggested to start at 0.5-1 mg/kg/day and to slower and cautiously increase by 0.5-1 mg/kg/day to a target dose of 2-3 mg/kg/day over few weeks. Heart rate and blood pressure should be monitored in the first 2-3 h after the first intake and at each dose increase. Suggestions to initiate the treatment as inpatients are made only for infants younger than 2 months, weight less than 2000 g, infant with inadequate social support, or comorbidities [6, 7].

Here we report the case of a severe cardiac adverse event in an otherwise healthy child on treatment with propranolol for IH. We believe the cardiac arrest was the consequence of an unfortunate combination of factors. The patient suffered from breath-holding spells and despite being usually a benign condition, it is potentially associated with neurally-mediated (vasovagal) phenomena [8]. In fact a painful or distressing event may induce a vagally mediated cardiac inhibition with prolonged asystole usually terminated by escape junctional beats or recovery of sinus rhythm. There are even reported cases of successful treatment of complicated severe BHS with pacemaker [8–10]. The patient performed a Valsalva’s maneuver that triggered a neurally-mediated syncope

| Table 1 | Panel of genes responsible for cardiomyopathies and channelopathies implicated in arrhythmias. Mutation of SCN9A has been associated to “Paroxysmal Extreme Pain disorder” which can present as breath-holding spells and episodes of extreme bradycardia in infancy |
|------------------|------------------|
| **Arrhythmias**  | **Cardiomyopathies** |
| ABC9             | ACTC1            |
| AKAP9            | ACTN2            |
| ANK2             | ANKRD1           |
| CACNA1C          | BAG3             |
| CACNB2           | BRAF             |
| CALM1            | CALR3            |
| CASQ2            | CAV3             |
| CAV3             | CRYAB            |
| DSC2             | CSRP3            |
| DSG2             | DES              |
| DSP              | DMD              |
| GJAS             | DTNA             |
| GPD1L            | EYA4             |
| HCN4             | FKTN             |
| JUP              | GATAD1           |
| KCNA5            | GLA              |
| KCND3            | JPH2             |
| KCNE1            | KRAS             |
| KCNE2            | LAMA4            |
| KCNE3            | LAMP2            |
| KCNH2            | LDB3             |
| KCNJ2            | MIB1             |
| KCNJ5            | MYBPC3           |
| KCNQ1            | MYH6             |
| KCNQ1            | MYH7             |
| LMNA             | MYL2             |
| NPPA             | MYL3             |
| NUP155           | MYOZ2            |
| PKP2             | MYPN             |
| RYR2             | NEXN             |
| SCN1B            | NF1              |
| SCN2B            | NNT              |
| SCN3B            | NRAS             |
| SCN4B            | PLN              |
| SCN5A            | PRDM16           |
| SNT1             | PRKAG2           |
| TGFB3            | PTPN1            |
| TEMEM43          | RAF1             |
| TRDN             | RBM20            |

| Table 2 | Single nucleotide polymorphisms (dbSNP) identified in genes encoding enzymes involved in propranolol’s metabolism and pharmacokinetics |
|------------------|------------------|
| **Gene**         | **locus**        | **dbSNP**  |
| CYP2D6           | 22q13.1          | rs16947    |
| CYP2C19          | 10q24            | rs17878459 |
| ORM1             | 9q32             | rs1126801  |
| UGT1A7           | 2q37             | rs374860015|
| UGT2B7           | 4q13             | rs138733571|

Table 1 | Panel of genes responsible for cardiomyopathies and channelopathies implicated in arrhythmias. Mutation of SCN9A has been associated to “Paroxysmal Extreme Pain disorder” which can present as breath-holding spells and episodes of extreme bradycardia in infancy (Continued)
which probably she didn’t recover from because she was dehydrated and beta-blocked so that it progressed to asystolic cardiac arrest. Finally the patient could have been a slower metabolizer of the drug, maintaining therefore higher plasmatic concentration than expected. Her CYP2D6’s variant is associated with a phenotype with decreased enzymatic activity [11–13], but we don’t know what is the effect of the other SNPs we identified and we can only speculate they could affect the pharmacokinetics of propranolol. Yet it is important to note that she didn’t show the signs of beta-blocker intoxication (i.e. hypotension, bradycardia, ECG abnormalities, hypoglycemia) once spontaneous circulation was restored.

Conclusions
The number of patients treated with systemic beta-blockers for IHs is expected to grow and some clinicians might even consider offering this effective treatment to children beyond the proliferation phase. In fact off-label use of propranolol after 5 months of age (as for our case) has frequently been described as successful in the literature [14–17]. The experience with this drug is therefore accumulating and we will gain more and more information on its effectiveness [18] and its possible side effects. If more of such severe adverse events were to be reported, we believe stricter indications and contraindications should be discussed.

Meanwhile if the treatment is to be offered to a child older than 6 months, a history of breath-holding spells needs to be investigated. We believe that this group of children should be treated with great caution since they have a higher risk to develop vagally mediated bradycardia.

It could be worth discussing if monitoring should be extended longer than few hours after initiation and if a Holter-ECG is to be considered once the target dose has been reached in order to detect possible episodic bradycardia, which might prompt dose reduction or treatment’s discontinuation.

As already recommended, it is important to strongly advise parents to seek for a doctor’s opinion and follow-up in case of intercurrent infections while on treatment; propranolol therapy should be temporarily withheld in case of intercurrent infections while on treatment; advise parents to seek for a doctor’s discontinuation.

Abbreviations
BHS: Breath holding spells; ECG: Electrocardiogram; ICU: Intensive Care Unit; IH: Infantile Hemangioma; SNP: Single nucleotide polymorphism

Acknowledgements
Dr. Irene A.B. Giovannini, MD contributed in the care of the patient and had a role in the writing of the manuscript.

Funding
No external funding for this manuscript.

Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Authors’ contributions
AT collected the information, drafted the initial manuscript. MDC performed molecular genetic analyses, critically reviewed and revised the manuscript. MC, AP, GP, SS critically reviewed and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable according to our Institutional Research Ethic Boards.

Consent for publication
Consent to publication was obtained from parents.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Women’s and Children’s Health, Pediatric Intensive Care Unit, University Hospital of Padua, via Giustiniani 3, 35128 Padova (PD), Italy.
2 Pediatric Dermatology Unit, “Dell’Angelo” Hospital, Venice, Italy.
3 Research&Innovation s.r.l., Padua, Italy. 4 Department of Women’s and Children’s Health, Pediatric Neurology and Neuropsychology, University Hospital of Padua, Padua, Italy.

Received: 8 August 2017 Accepted: 10 November 2017
Published online: 17 November 2017

References
1. Prey S, Voisard JJ, Delarue A, Lebbe G, Taieb A, Leauté-Labréze C, et al. Safety of Propranolol therapy for severe infantile Hemangioma. JAMA. 2016;315(4):413–5.
2. Hoeger PH, Harper JJ, Baselga E, Bonnet D, Boon LM, Ciofi Degli Atti M, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855–65.
3. Saidi W, Zouaui A, Saïhi N, Mokni S, Dengueudi M, Nouira R. Cardiorespiratory arrest following bronchiolitis in a child treated with propranolol for hemangioma. Annales de dermatologie et de venéreologie. 2014;41(8-9):552–9.
4. Leauté-Labréze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posituras G, et al. Randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–46.
5. Darrow DH, Greene AK, Mancini AJ, Nopper AJ, Section On Dermatology. Propranolol for severe infantile Hemangioma. JAMA. 2016;315(4):413–5.
6. Legge LM, Kantoch MJ, Seshia SS, Soni R. A pacemaker for asystole in complicated and refractory breath-holding spells associated with significant bradycardia: successful treatment with permanent pacemaker implantation. Pediatrics. 2001;108(3):698–702.
7. Kota NL, Kota SH, Kota SH. A pacemaker for asystole in breath-holding spells. Paediatr Child Health. 2002;7(4):251.
8. Metty DW, S Infantile hemangiomas: Management. Corona R, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed 28 Sept 2017.
9. Sarto S, Nosadini M, Leonl D, de Palma L, Toldo I, Mlanes O, et al. Pacemaker in complicated and refractory breath-holding spells: when to think about it? Brain Dev. 2015;37(1):2–12.
10. Kelly AM, Porter CJ, McGoon MD, Espinosa RE, Osborn MU, Hayes DL. Breath-holding spells associated with significant bradycardia: successful treatment with permanent pacemaker implantation. Pediatrics. 2001;108(3):698–702.
11. Legge LM, Kantoch MJ, Seshia SS, Soni R. A pacemaker for asystole in breath-holding spells. Paediatr Child Health. 2002;7(4):251–4.
12. Sowinski KM, Burlow BS. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response. Pharmacotherapy. 1997;17(6):1305–10.
13. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol’s metabolism is determined by both mephenytoin and debrisoquin hydroxylation activities. Clin Pharmacol Ther. 1989;45(1):72–9.
haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet. 2014;23(1):268–78.

14. El Hachem M, Gesualdo F, Dociiaia A, Berti I, Vercellino N, Boccaletti V, et al. Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience. Ital J Pediatr. 2017;43(1):40.

15. Vivas-Colmenares GV, Bernabeu-Wittel J, Alonso-Arroyo V, Matute de Cardenas JA, Fernandez-Pineda I. Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase. Pediatr Dermatol. 2015;32(3):348–52.

16. Albuquerque JC, Magalhaes RA, Felix JA, Bastos MV, Fontenele JB, Trompieri NM, et al. Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study. Sao Paulo medical journal = Revista paulista de medicina. 2014;132(1):48-54.

17. Zvulunov A, McCuaig C, Frieden IJ, Mancini AJ, Puttgen KB, Dohil M, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol. 2011;28(2):94–8.

18. Pratico AD, Caraci F, Pavone P, Falsaperla R, Drago F, Ruggieri M. Propranolol: effectiveness and failure in infantile Cutaneous Hemangiomas. Drug safety - case reports. 2015;2(1):6.